Handelsavisen
prelaunch
Companies Healthcare 241820.KQ
24
241820.KQ KOSDAQ Biotechnology & Medical Research

PCL Inc

Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-47,0 %
ROE
-10,2 %
Net margin
-53,7 %
Debt / equity
0,54
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

PCL Inc is a South Korean biotechnology company focused on the development and commercialization of innovative pharmaceutical products, primarily in the areas of oncology and autoimmune diseases.

Business. PCL Inc (241820.KQ) is a biotechnology and medical research company listed on the KOSDAQ exchange. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-10,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 241820.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 241820.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    PCL Inc (241820.KQ) is a biotechnology and medical research company listed on the KOSDAQ exchange. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Specific details regarding operating segments, headquarters location, and geographic presence are not available in the provided data.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    PCL Inc's capital structure is characterized by a debt-to-equity ratio of 0.54, indicating a moderate reliance on debt financing. The company holds cash and equivalents of KRW 6,397.8 billion, but this is offset by long-term debt of KRW 19,006.9 billion, resulting in a net cash position that is negative after subtracting total debt. The liquidity risk is rated as medium, with a current ratio of 1.55, suggesting the company has sufficient short-term assets to cover its short-term liabilities.

    Profitability metrics for PCL Inc are negative, with a return on equity of -10.15% and a return on assets of -5.79%. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit. The gross profit is negative at KRW -2,747.6 billion, and the operating income is also negative at KRW -3,148.0 billion, reflecting significant operational challenges.

    PCL Inc's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher risks if market conditions in its primary segment or region deteriorate.

    The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the available data. However, the negative operating cash flow of KRW -4,916.7 billion and free cash flow of KRW -3,122.6 billion suggest that the company is not generating sufficient cash from operations to sustain or grow its business without external financing.

    Risk factors for PCL Inc include a medium liquidity risk and a low dilution risk. The company's negative net cash position and significant long-term debt raise concerns about its ability to meet long-term obligations. The dilution risk is low, but the company may need to issue additional shares to fund operations or reduce debt, which could dilute existing shareholders' equity.

    Recent events and filings for PCL Inc include a significant net loss of KRW -3,601.3 billion for the period under review. The company has also reported negative operating and free cash flows, indicating ongoing financial stress. No recent transcripts or detailed filings are available to provide further insight into the company's strategic direction or operational performance.

    Key takeaways
    • PCL Inc is experiencing significant financial stress, with negative profitability and cash flow metrics.
    • The company's capital structure is moderately leveraged, with a debt-to-equity ratio of 0.54.
    • PCL Inc's return on equity and return on assets are both negative, indicating poor performance.
    • The company's liquidity position is medium risk, with a current ratio of 1.55.
    • PCL Inc's revenue is concentrated in a single segment, increasing its exposure to market-specific risks.
    • The company's growth trajectory is uncertain, with no clear signs of improvement in its financial performance.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 2

    Cash conversion of 1.37 places PCL Inc in the top quartile, exceeding the cohort median of 0.87.

    Dilution risk is assessed as low, providing some stability for existing shareholders amidst financial volatility.

    BEAR CASE · 2

    The company faces high credit risk, indicating significant concerns regarding its ability to meet financial obligations.

    A four-year revenue CAGR of -61.0% demonstrates a persistent and severe long-term decline in top-line growth.

    In focus — financials by report

    Annual
    ANNUALFiled 2022-02-14
    FY 2022 · Full-year highlights

    Revenue KRW 46.15B, −14,0% YoY; Operating income −200,3% YoY.

    RevenueKRW 46.15B−14,0 % YoY
    Operating income-KRW 25.77B−200,3 % YoY
    Net income-KRW 31.67B−262,3 % YoY
    Free cash flow-KRW 38.33B−312,6 % YoY
    EPS
    Operating cash flow-KRW 16.22B−609,5 % YoY
    Financials
    Income statement
    RevenueKRW 46.15B
    Gross profit-KRW 11.18B
    Operating income-KRW 25.77B
    Net income-KRW 31.67B
    Margins
    Gross margin-24.2%
    Operating margin-55.8%
    Net margin-68.6%
    FCF margin-83.1%
    Balance sheet
    Total assetsKRW 79.30B
    Total liabilitiesKRW 64.75B
    Total equityKRW 14.55B
    Cash & equivalentsKRW 38.22B
    Long-term debtKRW 33.91B
    Cash flow
    Operating cash flow-KRW 16.22B
    CapEx-KRW 8.69B
    Free cash flow-KRW 38.33B
    SBC
    P&L flow · revenue → net income
    Revenue KRW 6.70BOperating costs KRW 9.85BFinance KRW 388.9MNet income KRW 3.60B
    Highlights
    • Revenue KRW 46.15B, −14,0% YoY
    • Operating income −200,3% YoY
    • Net income −262,3% YoY
    • Free cash flow −312,6% YoY
    • Net margin -68.6%

    Valuation FY

    Market price
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $35.49B
    Net cash
    -$12.61B
    Current ratio
    1.6
    Debt / equity
    0.5
    ROA
    -5.8%
    ROE
    -10.2%
    Cash conversion
    137.0%
    CapEx / revenue
    -48.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-47,0 %Above median
    Net Margin-53,8 %Above median
    ROE-10,2 %Above median
    Capex / Rev-48,7 %Below median
    D/E0,54Bottom quartile
    Cash Conv1,37Above P75

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • PCL Inc Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    241820.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2022-02-14 14:59 UTCEARNINGSAnnual results — FY 2022 Revenue KRW 46.15B · Net KRW -31.67B
    2021-02-01 12:20 UTCEARNINGSAnnual results — FY 2021 Revenue KRW 53.68B · Net KRW 19.51B
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage